Trade

with

Synageva BioPharma Corp
(NASDAQ: GEVA)
AdChoices
73.14
-0.96
-1.30%
After Hours :
74.10
+0.96
+1.31%

Open

73.61

Previous Close

74.10

Volume (Avg)

246.81k (264.57k)

Day's Range

71.46-75.14

52Wk Range

44.54-119.42

Market Cap.

2.43B

Dividend Rate ( Yield )

-

Beta

0.55

Shares Outstanding

33.17M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 13.37M

    • Net Income

    • -95.45M

    • Market Cap.

    • 2.43B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,658.95

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.55

    • Forward P/E

    • -10.42

    • Price/Sales

    • 256.41

    • Price/Book Value

    • 4.33

    • Price/Cash flow

    • -19.57

      • EBITDA

      • -90.34M

      • Return on Capital %

      • -31.72

      • Return on Equity %

      • -33.40

      • Return on Assets %

      • -31.72

      • Book Value/Share

      • 16.90

      • Shares Outstanding

      • 33.17M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 97.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -7.02

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -31.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -8.29

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -1,658.01

            • 39.38

            • Net Profit Margin

            • -1,658.95

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -410.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 20.01

              • 2.92

              • Quick Ratio

              • 19.68

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 16.90

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -14.99

                • 196.08

                • P/E Ratio 5-Year High

                • -25.16

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.75

                • 124.82

                • Price/Sales Ratio

                • 250.00

                • 9.12

                • Price/Book Value

                • 4.21

                • 8.26

                • Price/Cash Flow Ratio

                • -19.57

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -33.40

                    (-1.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -31.72

                    (-6.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -33.40

                    (-1.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.02

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -95.90M
                  Operating Margin
                  -717.09
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -19.57
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  82.15%

                  Mutual Fund Ownership

                  59.88%

                  Float

                  53.39%

                  5% / Insider Ownership

                  4.88%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Columbia Acorn Fund

                  •  

                    2,493,309

                  • 2.93

                  • 7.52

                  • VA CollegeAmerica Small Cap World

                  •  

                    2,190,074

                  • 0.00

                  • 6.60

                  • American Funds IS® Gbl Sm Cap

                  •  

                    1,326,100

                  • -1.49

                  • 4.00

                  • VA CollegeAmerica New Economy

                  •  

                    1,036,598

                  • 3.81

                  • 3.13

                  • Bb Biotech AG

                  •  

                    898,476

                  • -4.41

                  • 2.71

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    866,624

                  • 0.00

                  • 2.61

                  • Fidelity® OTC Portfolio

                  •  

                    502,283

                  • 43.31

                  • 1.51

                  • Fidelity® Independence Fund

                  •  

                    475,000

                  • 0.00

                  • 1.43

                  • iShares Nasdaq Biotechnology

                  •  

                    439,930

                  • -0.69

                  • 1.43

                  • Fidelity® Growth Company Fund

                  •  

                    417,200

                  • 0.00

                  • 1.26

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    10,660,432

                  • +0.12%

                  • 32.15

                  • Capital Research Global Investors

                  •  

                    4,044,761

                  • +0.25%

                  • 12.20

                  • Columbia Wanger Asset Management LLC

                  •  

                    3,521,000

                  • +13.84%

                  • 10.62

                  • Fidelity Management and Research Company

                  •  

                    3,386,354

                  • +26.67%

                  • 10.21

                  • Vanguard Group, Inc.

                  •  

                    1,240,381

                  • +16.62%

                  • 3.74

                  • Capital World Investors

                  •  

                    943,698

                  • -8.24%

                  • 2.85

                  • BB Biotech AG

                  •  

                    898,476

                  • -4.41%

                  • 2.71

                  • Bellevue Asset Management AG

                  •  

                    898,476

                  • -4.41%

                  • 2.71

                  • BlackRock Fund Advisors

                  •  

                    866,311

                  • -3.46%

                  • 2.61

                  • Janus Capital Management LLC

                  •  

                    778,106

                  • -6.32%

                  • 2.35

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Pri...morevate Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a r...moreecombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.lessless

                  Key People

                  Mr. Sanj K. Patel

                  Director/CEO/President

                  Dr. Felix J. Baker,PhD

                  Chairman of the Board/Director

                  Mr. Carsten Boess

                  CFO/Senior VP

                  Mr. Anthony G. Quinn, M.D. PhD, FRCP

                  Chief Medical Officer/Executive VP/Other Corporate Officer

                  Mr. Chris Heberlig

                  Chief Accounting Officer/Vice President, Divisional

                  • Synageva BioPharma Corp

                  • 33 Hayden Avenue

                  • Lexington, MA 02421

                  • USA.Map

                  • Phone: +1 781 357-9900

                  • Fax: +1 781 357-9901

                  • synageva.com

                  Incorporated

                  1993

                  Employees

                  172

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: